Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -23.91%. A quarter ago, it was expected that this drugmaker would post a loss of $0.37 per share when it actually produced a loss of $0.34, delivering a surprise of 8.11%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Acadia, which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $90.07 million for the quarter ended March 2020, missing the Zacks Consensus Estimate by 3.36%.